Deal also includes Illumina processing 4,000 GSK disease samples for pharmacogenomics application.
GlaxoSmithKline (GSK) purchased 1,000 HumanHap550 BeadChips from Illumina. The agreement also includes the addition of a statement of work to utilize Illumina’s Fast-Track Genotyping Service to process approximately 4,000 disease samples for pharmacogenetics application.
By the end of 2006, Illumina will have genotyped more than 15,000 samples and reported nearly 3.5 billion genotypes to GSK. “This purchase follows shortly after GlaxoSmithKline expanded their initial scope of work for a multiyear, genotyping services agreement with Illumina, demonstrating their continued uptake of our technology,” said Jay Flatley, Illumina president and CEO.